Accessibility Menu
Vitrolife Ab (publ) logo

Vitrolife Ab (publ)(OM) VITR

Market CapSEK 12.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+2,245%
5 Year-82%
1 Year-31%
1 Month+10%
SEK 94.85
-0.68%
-0.65Today
Vitrolife Ab (publ) last closing stock price
MetricPriceDate
Last closeSEK 94.852026-08-31
Vitrolife Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.89%SEK 91.302026-08-24
1 month+10.16%SEK 86.102026-07-31
3 month-2.62%SEK 97.402026-06-02
Year to date-30.77%SEK 137.002025-12-30
1 year-30.56%SEK 136.602025-08-29
3 year-36.93%SEK 150.402023-09-01
5 year-82.39%SEK 538.502021-09-01
Since inception+2,244.5%SEK 4.072001-06-27

Vitrolife Ab (publ) Financials at a Glance

Market Cap

SEK 12.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 3.39B

Net Income (TTM)

-SEK 4.98B

EPS (TTM)

-SEK 36.79

P/E Ratio

-2.60

Dividend

SEK 1.10

Beta (Volatility)

1.16 (Average)

Price

SEK 94.85

Volume

173,981

Open

SEK 95.55

Previous Close

SEK 95.50

Daily Range

SEK 94.15 - SEK 95.75

52-Week Range

SEK 84.00 - SEK 153.50

Estimated Earnings Date

Oct 22, 2026

VITR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vitrolife Ab (publ)

Vitrolife AB (publ) is a medical technology company focused on developing, producing, and selling products for assisted reproduction. With a comprehensive range of tools for fertility treatments, Vitrolife operates globally, serving various markets including Europe, Asia, and the Americas.

Products and Services
  • Oocyte retrieval needles and sperm processing solutions
  • In vitro fertilization media, oils, and micromanipulation pipettes
  • Advanced equipment like EmbryoScope and Primo Vision systems
Growth Outlook
  • Revenue increased to SEK 857 million in Q2 2026, up from SEK 807 million in Q1 2026
  • Gross profit margin improved to 60.3% in Q2 2026, indicating operational efficiency
  • Strong international presence supports future market expansion opportunities
Financial Highlights
  • Net income of SEK 129 million reported in Q2 2026, reflecting positive growth
  • Operating income margin reached 23.1% in Q2 2026, showcasing profitability
  • Cash and cash equivalents totaled SEK 823 million as of June 30, 2026
Vitrolife AB (publ) has established itself as a leader in the medical devices sector, particularly in assisted reproduction technologies. The company's diverse product offerings cater to a growing global demand for fertility solutions, positioning it well for future growth. Recent financial performance indicates a positive trajectory, with significant revenue growth and improved profit margins. The strong cash position further enhances the company's ability to invest in research and development, ensuring continued innovation in its product lines. With a solid foundation and a commitment to advancing reproductive health, Vitrolife presents an intriguing opportunity for potential investors.
AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,103

CEO

Bronwyn Brophy O'Connor

Website

www.vitrolife.com

Headquarters

Gothenburg, VG 421 32, SE

VITR Financials

Key Financial Metrics (TTM)

Gross Margin

53.72%

Operating Margin

19.50%

Net Income Margin

-146.96%

Return on Equity

-53.29%

Return on Capital

6.48%

Return on Assets

-44.08%

Earnings Yield

-38.46%

Dividend Yield

1.15%

Payout Ratio

-2.99%

Stock Overview

Market Cap

SEK 12.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

135.42M

Volume

173.98K

Avg. Volume

296.04K

Financials (TTM)

Gross Profit

SEK 1.82B

Operating Income

SEK 661.00M

EBITDA

-SEK 4.43B

Operating Cash Flow

SEK 727.00M

Capital Expenditure

-SEK 114.00M

Free Cash Flow

SEK 613.00M

Cash & ST Invst.

SEK 823.00M

Total Debt

SEK 1.60B

Vitrolife Ab (publ) Performance Analysis

Vitrolife Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 3,234,000,00092.4%
20232023-12-31SEK 3,512,000,0008.6%
20242024-12-31SEK 3,609,000,0002.8%
20252025-12-31SEK 3,440,000,000-4.7%
Vitrolife Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.1%
Q42025-12-316.7%
Q12026-03-31-9.4%
Q22026-06-306.2%
Vitrolife Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 2.91-2.2%
20232023-12-31SEK -28.44N/A
20242024-12-31SEK 3.79N/A
20252025-12-31SEK -37.01N/A
Vitrolife Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.4%
Q42025-12-31-5332.0%
Q12026-03-31101.9%
Q22026-06-3028.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 857.00M

-1.6%

Gross Profit

SEK 517.00M

+2.4%

Gross Margin

60.33%

N/A

Market Cap

SEK 12.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

SEK 11.73M

N/A

Employees

1,103

N/A

Net Income

SEK 129.00M

+29.0%

EBITDA

SEK 258.00M

+6.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 823.00M

-10.6%

Total Debt

SEK 1.60B

-19.7%

Accounts Receivable

SEK 844.00M

+9.8%

Inventory

SEK 440.00M

+2.3%

Long Term Debt

SEK 1.56B

-15.4%

Short Term Debt

SEK 45.00M

-70.6%

Return on Assets

-44.08%

N/A

Return on Invested Capital

6.18%

N/A

Free Cash Flow

SEK 106.00M

+107.8%

Operating Cash Flow

SEK 140.00M

-7.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About VITR

What is the current price of Vitrolife Ab (publ)?

Vitrolife Ab (publ) is trading at SEK 94.85 per share.

What is the 52-week range for Vitrolife Ab (publ)?

Over the past 52 weeks, Vitrolife Ab (publ) has traded between SEK 84.00 and SEK 153.50.

How much debt does Vitrolife Ab (publ) have?

As of the most recent reporting period, Vitrolife Ab (publ) reported total debt of SEK 1.60B.

How much cash does Vitrolife Ab (publ) have on hand?

Vitrolife Ab (publ) reported SEK 823.00M in cash and cash equivalents in its most recent financial results.

What is Vitrolife Ab (publ)’s dividend yield?

Vitrolife Ab (publ) currently has a dividend yield of 1.15%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services